Evidence map›Paper›PMID 35930206›Full record

ArticleJournal of computer-aided molecular design2022

Modeling receptor flexibility in the structure-based design of KRAS

Kai Zhu, Cui Li, Kingsley Y Wu, Christopher Mohr, Xun Li, Brian Lanman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of computer-aided molecular design, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Cryo-EM structure determination of small therapeutic protein targets at 3 Å-resolution using a rigid imaging scaffold.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  9. Article
  10. Inhibition mechanism of MRTX1133 on KRASJournal of computer-aided molecular design · 2023
    Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kai ZhuDepartment of Molecular Engineering, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320, USA. kzhu@amgen.com.
Cui LiAmgen Asia R&D Center, 13th Floor, Building No. 2, 4560 Jinke Road, Zhangjiang, Shanghai, 201210, China.
Kingsley Y WuDepartment of Chemistry, University of California, 501 Big Springs Road, Riverside, CA, 92521, USA.
Christopher MohrDepartment of Molecular Engineering, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320, USA.
Xun LiAmgen Asia R&D Center, 13th Floor, Building No. 2, 4560 Jinke Road, Zhangjiang, Shanghai, 201210, China.
Brian LanmanDepartment of Medicinal Chemistry, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

KRAS has long been referred to as an 'undruggable' target due to its high affinity for its cognate ligands (GDP and GTP) and its lack of readily exploited allosteric binding pockets. Recent progress in the development of covalent inhibitors of KRAS

Indexed as

Proto-Oncogene Proteins p21(ras)Guanosine TriphosphateLigandsMutationProtein ConformationGuanosine TriphosphateLigandsProto-Oncogene Proteins p21(ras)Binding affinityCovalent dockingFree energy perturbation (FEP)Pose predictionSwitch-II pocket

Identifiers

PMID35930206
PMCPMC9512760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.